

	Protokol	behandlings-linje	Fase	Alder	Diagnose	Behandling/Undersøgelse	Ansvarlig
MM	BP42233 Grace	R/R MM	I		MM	Ro7425781 in participants with relapsed or refractory multiple myeloma	CR/Siri - Marion
	CARTITUDE-5	R/lenalidomide R	III	non-HDT	MM	JNJ-68284528 (CAR-T) Therapy vs PVD or DPd in pt with R/Len -Refractory MM	AM/Sabrine (Emilie F)
	Majestec-3	R/len R 1-3 tidl linjer	III		MM	Tec-Dara vs DPd in pt with R/R MM	AM/Maria S (Marion/Tina)
	Vertebroplastik	1. Linje	III		MM	Vertebroplastik vs SOC til pt med symptomgivende columna forandring.	Jana
	ITHACA	Smouldering MM	III		MM	Isatuximab len-dex vs len-dex in patients with high-risk smoldering multiple myeloma	TD/Louise (Marion/Jytte)

MM lukkede	GO41582	R/R	I		MM	RO7297089 i patienter med R/R MM	AV/Maria S. (Marion)
	CARTITUDE-4	R/R	III		MM	CAR-T Therapy in Relapsed and Len-Refractory MM	AM/Sabrine - Maria S - Cæcilie
	HOVON 129		III		MM PCL	Carfilzomib and lenalidomide-based treatment	AV/Cæcilie - Maria S
	Perseus		III		MM	Phase 3 Study Comparing D-VRD vs VRD in newly dx HDT eligible MM	AV/Maria L Siri (Tina)
	Millenium C16019		III		MM	maintenance	CH/Louise
	Millenium C16021		III		MM	maintenance	CH/Louise
	Magnolia		II		MM	Zometa	CH/Marion
	M15-654	R/R	I		MM	A Phase 1/2 Study of Venetoclax, Daratumumab Dexamethasone (With and Without Bortezomib) in R/R MM pt.	AV/Maria S (M-T)
	HOVON 95		III		MM	Phase III study of VMP + HDT follow. by VRD+rev in pt with newly dx MM	PG/Marion
	HOVON 126		III		MM	Ixazomib+thalidomide follow. by ixazomib or placebo in newly MM	AV/Maria S
	Aquilla		III		MM	Phase 3: Daratumumab(sc) Vs Active Monitoring in High-risk SMM	AM/Marion
	Con-Pet		II		MM	KRd consolidation in PET+ MM after HDT. A phase II study	AV/Marion
	QoL MM				MM	Livskvalitet hos danske patienter med myelomatose QoL-MM	CH/Cæcilie
	CC92480-001	R/R	I		MM	CC-92480 (Cereblon-modifying agent) IN R/R MM.	AV/Claudia

YMFO	GCT3009-01	2+ R/R	I/II		NHL SLL/CLL	GEN3009 (DuoHexaBody®-CD37) in RR NHL and SLL/CLL	MH/Cæcilie
	Echelon 3 (SGN35-031)	R/R B-NHL	III		DLBCL	Brentux or Placebo with Lenalidomide and Rituxi in pt with R/R DLBCL	AG/Louise - Jytte
	MK-7684A-004		1b		HL, B-NHL	Vibostolimab with Pembrolizumab Coformulation in Pt R/R Hematological Malignancies	MH/Emilie F. - Claudia
	BP43131	R/R B-NHL	I		NHL	Ro7443904 with glofitamab in pt r/r B-nhl	MH/ Claudia - Emilie F - Tina
	NP30179	R/R B-NHL	I		NHL	phase II study of glofitamab as a single agent and in Combination with obinutuzumab in pt. with R/R B-NHL	MH/Karina - Claudia
	BP41072	R/R B-NHL	I		NHL	Ro7227166 (a cd19 targeted 4-1bb ligand) with obinutuzumab and glofitamab in pt r/r B-nhl	MH/ Karina - Nikoline
	LYM1002	R/R NHL	1B		NHL/CLL	Phase 1b Study of JNJ-67856633 and Ibrutinib/R/R B-NHL and CLL	MH/ Louise - Chris (Claudia)

L	BP43015	R/R NHL	1B		NHL	A phase 1B study to evaluate the safety, tolerability, PK, PD and efficacy of sc glofitamab in pt with r/r CD20+ B-NHL	MH/ Claudia
	NP39488	R/R B-NHL	I		NHL	An open-label, multi-center, phase Ib study of ro7082859glofitamab and atezolizumab or polatuzumab vedotin in R/R B-NHL	MH/Claudia (Karina)
	IMG, substudy NP39488	1B	I		NHL	Phase Ib imaging sub-study of glofitamab using ⁸⁹ Zr-DF-IAB22M2C as CD8 tracer in pt with r/r B-NHL	MH/Claudia (Karina)
	GCT3013-01	2.+	I		NHL	A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with R/R B-NHL	MH/Maria S - Sabine
	GCT3013-02		I		NHL	A Phase 1b/2 of epcoritamab in Combination with Other Agents in Subjects with B-NHL	MH/Sabrine - Louise
	NP40126	1.+	I		NHL	A phase 1b study evaluating ro7082859 with rituximab (r) or Obinutuzumab (g) plus CHOP in R/R NHL or untreated DLBCL	MH/Nikoline (Claudia, Karina)
	Nivo_ALCL	R/R	II		ALCL ALK+	Participants with Relapsed or Refractory ALK+ ALCL	PB
	Polar-bear	Diagnose	III	≥80 + ≥75 frail	DLBCL	R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin in pt with newly dx DLBCL, ≥80 years, or frail ≥75 years	PB/ Celina (Claudia)
	GO41944 (Starglo)	R/R	III	non-HDT	DLBCL	Efficacy and safety of glofitamab in Combination with Gem-Ox versus R-Gem-Ox in patients with r/r dlbl	PB/ Celina - Sabine (Laura)
	DLBCL-Pro				DLBCL efter behandl	Undersøge om symptomspørgeskema kan prædiktere relaps hos patienter, som har gennemført 1. linje kurativ behandling for DLBCL	TL Ph.D
	DELPHI	R/R	observationelt	≥60	B-NHL	Prædiktion af hematologisk toksitet vha. NGS og livskval. undersøgelse	Simon Husby
	Stay Strong	1.			Lymfom	Tab af skelet muskelmasse under Antracyclin-holdig kemoterapi	MH/Charlotte Grønset
	CNSctDNA	Mistanke om CNS-involvering Alle			DLBCL relaps (CNS)	Spinalvæske + bl. Pr.	ERT Ph.D

LYMFOM lukkede	Echelon 1	1.	III		Mb Hodgkin	A+AVD Versus ABVD as Frontline Therapy in Pt With Advanced cHL	LS/Louise - Jytte
	IELGS 32	1.	II		CNS lymfom	RANDOMIZED PHASE II TRIAL FOR PT WITH PRIMARY CNS LYMPHOMA	LE/Jytte
	Cobra	1.	II		St 2B-IV.	Very early PET adapted therapy for advanced cHL	MH/Claudia - Karina
	Enrich	1.	II		Mantlecelle	Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older pt with MCL	MH/Celina - Karina - Jytte
	Chronos 4	2+	III		NHL	Standard immunochemotherapy +/- Copanlisib (PI3K inh) in R iNHL	MP/Louise
	Citadel-801	2+	I		FL	INCB050465 With Bendamustine and Obinutuzumab in Pt with R/R FL	MH/Karina
	SAKK 3510	1.	II		FL	Rituximab plus +/- Lenalidomide for pt with foll. lymf in need of therapy	PB/Celina - Karina
	SAKK 3514	1.	II		FL	Rituximab +/- Ibrutinib for follicular lymphoma pt. in need of therapy	MP/Celina - Karina
	BIOCHIC	1.	II	<65	NHL	Biomarker driven DI treatment with CNS proph. in high risk DLBCL < 65	PB/Sabrine - Karina
	Preben	2+	II		NHL	Pixantrone, etoposide, bendamustine and rituximab in relapse NHL pt	PB/Sabrine - Karina
	Valeria	2.	II		NHL	Venetoclax, lenalidomide and rituximab in pts with r/r MCL	MH/Chris - Siri M
	Vitality		mænd	18->65y	DLBCL + HL	Testosteron gel	SMP Ph.D
	Triangle	1.	III	<65	Mantlecelle	ABMT after a Rituximab/Ibrutinib/Ara-c induction in MCL	MH/Celina

J	LYM1002	R/R	1B		CLL/NHL	Phase 1b Study of JNJ-67856633 and Ibrutinib in R/R B-NHL and CLL	MH/Claudia - Chris - Louise
	GCT3013-03	R/R	Ib/II		CLL	Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in R/R CLL	CN/Maria S - Christina

CLI	CLL-RT1	Richter	II		CLL	Zanubrutinib (bgb-3111), a BTK inhibitor, plus tislelizumab (bgb-a317), a pd-1 inhibitor, for treatment of patients with Richter transformation	CN/Marion - Maria L
	CLL-17	1.	III		CLL	Ibrutinib vs Venetoclax plus Obinutuzumab versus Ibrutinib plus Venetoclax in pt with previously untreated CLL	CN/ Katrine - Signe - Pia - Christina
	Prevent-ACall	Dx < 1 år			CLL	Acalabrutimib + venetoclax	CN/Christina - Cæcilie
CLL lukkede	CLL-13	1	III		CLL	FCR/BR VS RVE VS GVE VS GIVE IN FIT CLL (no 17p or TP53)	CN/Pia - Julie
	CLL-14	1	III		CLL	OBI + VENETOCLAX VS OBI-CHLOR IN CLL WITH COMORBIDITY	CN/Julie - Pia
	ASSURE	1	III		CLL	Acalabrutinib in CLL	CN/Pia - Julie - Signe
	GLOW	1	III		CLL	Ibrutinib + Venetoclax vs Obi-Chlor in CLL/SLL	CN/Katrine - Cæcilie - Lone
	ACE-CL-311	1	III		CLL	Acalabrutinib + Venetoclax +/- Obinutuzumab Compared IC in CLL	LE/Emma - Jytte
	Venice ext M19-388	1	IIIB		CLL	Venetoclax in R/R CLL	LE/Jytte
	HOVON158	1	III		CLL	VeNetoclaX + ibrutinib --> obinutuzumab for CLL/SLL Pt not in CR/MRD+	CN/Katrine - Dorte
	BRF/roll over	alle	NA		HCL	Roll-over study in dabrafenib / trametinib treated pt.	JM/ Dorte - Marie-Therese
	Murano	2+	III		CLL	VENETOCLAX + RITUXIMAB VS R-BENDAMUSTINE in R/R CLL	CN/Maria S
	VISION	2+	II		CLL	Ibrutinib + venetoclax in R/R CLL (no 17p/TP53)	CN/Julie - Emma
AML/ALL & MDS	WP42004	R/R AML	I		AML HLA-A	Ro7283420 as a single agent in hematologic and molecular r/r AML	MH/Christel-Signe - Marie-Therese
	LDVendEx	de novo +R/R	II		AML unfit eller R/R	Azacitidine in combination with Low Dose Venetoclax for AML pt	KT/AL/Julie - Christel
	Alltogether	1.	III	01.-45.	ALL	Protocol for children and young adults with newly diagnosed ALL	UO/Laura - Emma
	AML 18	1.	II/III	≥ 60	AML	AML treatment, older patients	UO/Marie-Therese
	Evi2	1.	II		CCUS	ascorbic acid single drug to CCUS	Astrid
	Evi3	1.	II		MDS/AML	azacytidine + ascorbic acid in high-risk MDS, CMML-2 or low-blast AML	Astrid
	STOP Leukemia	1.	II		CCUS/MDS	Repurposing metformin in CCUS and LR-MDS	Krista
	Cassiopeia	1.	II	-25	ALL (CAR-T)	Tisagenlecleucel in pt. with HR B-ALL MRD+ at the end of consolidation	SP/Marie-Therese - Emma
AML/ALL MDS lukkede	AML-LI						LK/Marie-Therese
	NOPHO				ALL	Follow up	UO/Jytte
	AML 19	1	II/III	-60	AML	AML treatment, younger patients	UO/Marie-Therese
MPN							
MPN lukkede	Bosupeg		III		CML	A study of efficacy and safety	MBC/Dorte - Jytte
	ADORE		I/II		MF	Ruxolitinib combinations in myelofibrosis patients	CR/Marie-Therese
	ASC4MORE				CML	Oral asciminib added to imatinib vs imatinib vs switch to nilotinib in CML-CP ptnot in DMR	MBC/Signe - Jytte

HÆMOFI LI	Explorer-8	NA	IIIa		Hæmofili A el B	Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B without inhibitors	EF/Tina
	Frontier-2	NA	III		Hæmofili A	Efficacy and safety of NNC0365-3769 (Mim8) in pt with haemophilia A with or without inhibitors	PK/Christel - Thilda

HÆMOFI lukkede	HOPE	NA			Hæmofili B	Phase III study of serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene in pt with severe or moderately severe hemophilia B	PK/Tina - Thilda
	Atlas-OLE	NA	II		Hæmofili A/ B	Phase II study of Fitusiran in Pt with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX	PK/Thilda - Christel

BENIGN HÆMATOLOGI åben	Autoimmunity in BM failure syndromes	Ved dx el. senere			PNH, MDS, AA, LGL leukemia	100 ml blod og/eller 20 ml KM og/eller fæcesprøve til us (post doc)	GL/Jytte
	MiniBridge		III		BAT >=4 ♂ BAT >=6 ♀	Functional and Genetic Characterization of Platelets in Patients Suspected of a Bleeding Disorder	EL/Christel
	Neutropeni beh. SCNIR	Alle			Kronisk neutropeni ANC < 0,5 (ved inf. ANC < 1,0)	Register us.	GL/Jytte
	Peak registry AG348-C-008	Alle			Pyruvatkinasemangel	Registreringsstudie	GL/Lone - Jytte
	Natron		III		HES	24-week Benralizumab Study of efficacy and Safety of Benralizumab in Hypereosinophilic Syndrome pt	CLA/Christina - M-T

Ben hæm luk	AG348-C-011				PKD	AG-348 IN PT WITH PKD PREVIOUSLY ENROLLED IN AG-348 STUDIES	GL/Lone - Jytte
-------------------	-------------	--	--	--	-----	---	-----------------

KMT	Cassiopeia	KMT/ALL	II		ALL	A phase II trial of tisagenlecleucel in 1. line HR B-ALL who are MRD + at EOC therapy	SL/Marie-Therese -Emma
	PAVO	CAR-T	IV		ALL	Long Term FUP of Pt Exposed to Lentiviral- Based CAR T-Cell Therapy	SLP/Emma - Marie-Therese

KMT lukkede	REACH-3	KMT				Phase III study of ruxolitinib vs. BAT in pt with ster. refractory cGVH	BK/Emma
	Gravitas	GVH	II/III			Itacitinib and Corticosteroids as Initial Treatment for Chronic GVH	BK/Thilda - Dorte
	MORPHO	KMT				Phase III Trial of Gilteritinib after Allogeneic Tx for FLT3/ITD AML	BK/Thilda

[Link til telefonliste:](#)